SETH LERNER to Genetic Vectors
This is a "connection" page, showing publications SETH LERNER has written about Genetic Vectors.
Connection Strength
0.657
-
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
Score: 0.161
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.136
-
Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. Anticancer Res. 2000 Sep-Oct; 20(5A):2811-6.
Score: 0.134
-
Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997 Feb; 49(2):173-80.
Score: 0.105
-
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
Score: 0.034
-
Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 2000 May-Jun; 20(3A):1359-65.
Score: 0.033
-
Current status of gene therapy for prostate and bladder cancer. Int J Urol. 1997 Sep; 4(5):435-40.
Score: 0.027
-
Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
Score: 0.027